We are focused on developing differentiated products for the treatment and prevention of serious infectious diseases. Our clinical-stage programs include FV-100, a potent, orally available, antiviral for the treatment of herpes zoster (shingles), and Aurexis^®, a humanized monoclonal antibody for the adjunct treatment of serious S. aureus infections. Antiviral programs in pre-clinical development include differentiated oral compounds for the treatment of HCV.